Atlas Trials

Phase 1b Study of Pegylated Liposomal Doxorubicin and Pembrolizumab in Endocrine-resistant Breast Cancer

Clinical trial NCT03591276 · RECRUITING

Trial details

NCT number
NCT03591276
Sponsor
Shaare Zedek Medical Center
Status
RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Breast Cancer
Start date
2019-04-18
Primary completion
2021-04-15
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.